Ozempic vs Mounjaro vs Wegovy in Canada: 2026 Side-by-Side Comparison of Access, Approval, and Weight-Loss Resultssults
Three GLP-1 receptor agonist medications dominate the Canadian weight-loss and diabetes conversation in 2026: Ozempic, Wegovy, and Mounjaro. They share an active mechanism but differ in molecule, dosing, Health Canada-approved indication, average weight loss, side-effect profile, and details. This deep comparison breaks down each medication, the clinical-trial evidence, Canadian prescribing steps, safety considerations, and how to switch between them safely under doctor supervision.
Book Your Appointment Now
Ozempic and Wegovy both contain semaglutide, while Mounjaro contains tirzepatide — a dual GIP/GLP-1 agonist. As of 2026 in Canada, Health Canada has approved Ozempic for type 2 diabetes (2018), Wegovy for chronic weight management (2021), and Mounjaro for type 2 diabetes (2023). Average weight loss is 12-15% for Ozempic, 15-20% for Wegovy, and 18-22% for Mounjaro across pivotal trials.
- Ozempic received Health Canada Notice of Compliance in January 2018; Wegovy in November 2021; Mounjaro in November 2023.
- Mounjaro (tirzepatide) is the only dual GIP and GLP-1 receptor agonist available in Canada — the others target only GLP-1.
- STEP-1 trial showed Wegovy users lost an average of 14.9% body weight over 68 weeks; SURMOUNT-1 showed Mounjaro users lost up to 22.5% over 72 weeks.
- A licensed doctor reviews your intake before the visit and explains the safest next step.
Clinical content is reviewed for accuracy and scope. TelePlus Care appointments proceed only when clinically appropriate after a real assessment, and the doctor will explain the next step if virtual care is not the right fit.
What Is a GLP-1 Receptor Agonist?
Glucagon-like peptide-1 (GLP-1) is a hormone released by the small intestine after meals. It signals the pancreas to produce insulin, slows the rate at which food empties from the stomach, and acts on the brain's appetite centres to promote satiety. GLP-1 receptor agonists are synthetic peptides that mimic this hormone's effects but persist in the body far longer than the natural version. The class has been used to treat type 2 diabetes for over 15 years; weight-loss applications became prominent after 2017 when high-dose semaglutide produced dramatic results in clinical trials. Mounjaro extends the concept by also activating the GIP receptor, doubling the metabolic targets.
Ozempic (Semaglutide) — The Original Mainstream GLP-1
Ozempic is Novo Nordisk's once-weekly subcutaneous semaglutide injection. Health Canada approved it in January 2018 for adults with type 2 diabetes as an adjunct to diet and exercise. Available doses are 0.25 mg, 0.5 mg, 1 mg, and 2 mg, dispensed in pre-filled multi-dose pens. Although Ozempic is not approved by Health Canada specifically for weight management, off-label prescribing for obesity is legal and widespread when clinical criteria are met. The SUSTAIN trial program and the STEP-2 trial have demonstrated 12 to 15 percent average weight loss in patients taking Ozempic at the 1 mg or 2 mg dose for 52 to 68 weeks.
Wegovy (High-Dose Semaglutide) — Built for Weight Loss
Wegovy is also semaglutide but at a higher maximum dose of 2.4 mg weekly, formulated specifically for chronic weight management. Health Canada approved Wegovy in November 2021 for adults with a body mass index of 30 kg/m squared or greater, or 27 kg/m squared or greater with at least one weight-related comorbidity. In June 2023 Health Canada extended the indication to adolescents aged 12 and older. The pivotal STEP-1 trial showed an average weight loss of 14.9 percent over 68 weeks compared with 2.4 percent for placebo. Wegovy's 2024 SELECT trial also demonstrated a 20 percent reduction in major adverse cardiovascular events in overweight or obese adults with established cardiovascular disease.
Mounjaro (Tirzepatide) — The Dual-Agonist Newcomer
Mounjaro is Eli Lilly's once-weekly tirzepatide injection. Health Canada granted Notice of Compliance in November 2023 for adults with type 2 diabetes, with doses of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. The breakthrough is that tirzepatide activates both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor — making it a dual incretin agonist. The SURMOUNT-1 trial in adults with obesity showed up to 22.5 percent average body weight loss at the 15 mg dose over 72 weeks. As of 2026, Mounjaro is approved in Canada for type 2 diabetes only, while its weight-loss-indicated counterpart Zepbound has not yet received Health Canada approval at the time of this update — doctors prescribe Mounjaro off-label for weight management when criteria are met.
Side-by-Side: Approval, Indication, and Active Ingredient
Knowing exactly what each medication is approved for in Canada matters because it determines pharmacy availability and prescriber comfort. Off-label prescribing is legal but plans rarely support off-label use without strong documentation.
- Ozempic — semaglutide; Health Canada-approved for type 2 diabetes (2018); off-label for weight loss.
- Wegovy — semaglutide (high-dose); Health Canada-approved for chronic weight management (2021); also approved for cardiovascular risk reduction in obese adults (2024).
- Mounjaro — tirzepatide; Health Canada-approved for type 2 diabetes (2023); off-label for weight loss.
- All three: subcutaneous once-weekly injection in a pre-filled pen.
- All three: distributed by major Canadian wholesalers and dispensed at Shoppers Drug Mart, London Drugs, Rexall, Costco, and other pharmacies.
Average Weight-Loss Results: What the Trials Show
Direct head-to-head trials between all three medications are limited, but pivotal studies allow reasonable comparison. Across these large randomized trials in patients with obesity (with or without type 2 diabetes), tirzepatide consistently produces the greatest weight loss, followed by high-dose semaglutide, with standard-dose semaglutide trailing — though all three substantially outperform placebo and lifestyle interventions alone.
- Ozempic 1 mg weekly — 9.6% mean body weight loss at 68 weeks (SUSTAIN trials).
- Ozempic 2 mg weekly — 11 to 15% mean weight loss at 40 weeks (STEP-2).
- Wegovy 2.4 mg weekly — 14.9% mean weight loss at 68 weeks (STEP-1).
- Mounjaro 10 mg weekly — 19.5% mean weight loss at 72 weeks (SURMOUNT-1).
- Mounjaro 15 mg weekly — 22.5% mean weight loss at 72 weeks (SURMOUNT-1).
- Placebo with lifestyle: typically 2-3% over the same trial duration.
Canadian appointment steps in 2026
Your intake helps the clinician understand your symptoms, history, and goals before the visit.
- The booking team confirms appointment timing, intake needs, and follow-up expectations before your visit.
- Your care team confirms the visit steps, intake requirements, and follow-up plan before the appointment.
- A licensed doctor reviews your intake before the visit and explains the safest next step.
- Your intake helps the clinician understand your symptoms, history, and goals before the visit.
What should I know before booking?
access depends on indication, plan, and province. Your doctor reviews medication options, pharmacy steps, and follow-up needs during the appointment. clinical access pathways for weight-management indications is rare across all provinces. Your pharmacist can confirm medication-specific next steps. Always confirm using the DIN: Ozempic 02471477, Wegovy 02525155, Mounjaro 02538419.
Side Effects — How They Compare
All three medications share the GLP-1 side-effect profile because they share much of the same mechanism. Most adverse events are gastrointestinal and most resolve within 8 to 12 weeks as the body adapts. Mounjaro's GIP component does not appear to dramatically increase nausea relative to semaglutide. The frequency of nausea, vomiting, diarrhea, and constipation is generally similar across all three at comparable doses.
- Common (more than 10% of users): nausea, vomiting, diarrhea, constipation, abdominal pain, decreased appetite.
- Less common (1-10%): fatigue, headache, dizziness, injection-site reactions, gallstones.
- Rare but serious: pancreatitis, kidney injury from dehydration, gallbladder disease, hypoglycemia (especially in patients also on insulin or sulfonylureas).
- Boxed warning: thyroid C-cell tumours observed in rodents — contraindicated for those with personal/family history of medullary thyroid carcinoma or MEN-2.
Which One Is Right for You? A Decision Framework
The best medication depends on your primary goal, comorbidities, pharmacy availability, and tolerance. There is no universal winner. Use this framework as a starting point for the discussion with your prescriber.
- Type 2 diabetes with modest weight goal: Ozempic — established safety, broadest access, lower details.
- Type 2 diabetes with significant weight goal: Mounjaro — superior glycemic and weight outcomes.
- Weight management without diabetes, BMI 30+: Wegovy — Health Canada-approved indication; best private access.
- Weight management with cardiovascular disease: Wegovy — SELECT trial showed 20% MACE reduction.
- details-sensitive without benefits: Ozempic — lowest list details.
- Greatest weight-loss potential: Mounjaro 15 mg — up to 22% in SURMOUNT-1.
Switching Safely Between Ozempic, Wegovy, and Mounjaro
Switching between GLP-1 medications should always be supervised by a doctor. Although the molecules are related, dose equivalence is not exact, and abrupt switches can cause excessive nausea or transient loss of glycemic control. The general approach is to discontinue the current medication for one week (allowing the long half-life to clear), then start the new medication at its standard initiation dose. Physicians titrate up over the following 4 to 16 weeks based on tolerance and response. Patients moving from Ozempic 2 mg to Wegovy 2.4 mg often skip the lowest Wegovy doses; those moving to Mounjaro typically restart at 2.5 mg and titrate normally because of the different mechanism.
Canadian Supply and Availability in 2026
After the 2022-2024 shortage of Ozempic and Wegovy, Novo Nordisk dramatically expanded production at its Kalundborg and Clayton facilities, and as of 2026 supply is stable across Canada. Mounjaro had its own brief supply pressure in 2024 as Eli Lilly scaled the Indianapolis and Concord, North Carolina plants; supply normalized by Q1 2025. Health Canada's drug shortages portal (drugshortagescanada.ca) is the authoritative source for real-time status. Compounded versions of semaglutide and tirzepatide are not permitted by Health Canada outside narrow exceptions now that branded products are widely available.
Talk to a Canadian Physician About the Right GLP-1 for You
TelePlus Care offers virtual GLP-1 consultations with licensed doctors. We assess your goals, review your blood work and medical history, discuss medication details that may help your pharmacy, and prescribe the medication that fits your situation — Ozempic, Wegovy, or Mounjaro. Same-day appointments are available, prescriptions can be filled at your chosen pharmacy, and follow-up visits are scheduled to monitor response and adjust dose.
Your Fast and Convenient Healthcare Solution
Connect with a licensed healthcare provider from the comfort of your home. No referral needed — book your virtual appointment today.
Book Your Appointment Now
Teleplus care clinic is not an urgent care clinic. If you have an emergency please call911 or go to the nearest urgent care facility.
